Publications by authors named "Patricia Wongsodirdjo"
Background: Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer's disease. Such antibodies, however, are expensive and timely to produce and require frequent dosing regimens to ensure disease-modifying effects. Synthetic in vitro-transcribed mRNA encoding antibodies presents a promising alternative to conventional passive immunotherapy and overcomes the need to generate recombinant antibodies.
View Article and Find Full Text PDFCells have developed a highly regulated system for the uptake, transport, utilization, storage, and export of metals, ensuring the maintenance of cellular homeostasis. Small extracellular vesicles (sEVs) function as a mechanism through which a cell can export its cargo and transfer it to recipient cells. However, in contrast to the other molecular cargo associated with sEVs, the metal content of sEVs is not well characterized.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies, like lecanemab and aducanumab, have been recently approved in the USA as treatments for Alzheimer's disease, although they are costly and require frequent administration.
- Researchers are exploring synthetic messenger RNA (mRNA) as a new method to produce antibodies, potentially addressing the limitations of traditional antibody production.
- This study successfully created synthetic mRNA for a tau-specific antibody, demonstrating its effectiveness in producing functioning antibodies and targeting intracellular tau, which could benefit Alzheimer's and related diseases.